Table 4.
Lorlatinib treatment for ALK+ IMT
| Authors | Age (year) | Sex | ALK fusion | ALK inhibitor | Line | Response | PFS (months) | Other treatment |
|---|---|---|---|---|---|---|---|---|
| Kyi et al. [65] | 68 | F | TNS1-ALK | Lorlatinib | 4th | Clinical PD | 1 | Crizotinib (1st), alectinib (2nd), ceritinib (3rd) |
| 61 | F | LBH-ALK | Lorlatinib | 4th | PR | 3 | Crizotinib (1st), ceritinib (2nd), liposomal doxorubicin (3rd) | |
| Wang et al. [99] | 42 | F | PRRC2B-ALK | Lorlatinib | 4th | SD | 5+ | Crizotinib (1st), alectinib (2nd), ceritinib (3rd) |
| Wong et al. [108] | 40 | M | TPM4-ALK | Lorlatinib | 4th | SD | 6 | Prednisolone (1st), entrectinib (2nd), ifosfamide and etoposide (3rd), brigatinib (5th) |
| Yuan et al. [109] | 18 | F | NR | Lorlatinib | 4th | CR | 42+ | Crizotinib (1st), ceritinib (2nd), alectinib (3rd) |
M male, F female, PD progressed disease, SD stable disease, CR complete response, OS overall survival, NR not reported, ALK anaplastic lymphoma kinase, PRRC2B proline rich coiled-coil 2B, TNS1 tensin 1, LBH Limb Bud-Heart, TPM4 tropomyosin 4